Page 4 - சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adding PD-1 Inhibitor Shows Promise in Potentially Resectable HCC

Adding PD-1 Inhibitor Shows Promise in Potentially Resectable HCC
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.

United statesFort pierceInnovent biologicsLi xuEd susmanSun yat sen university cancer centerMedpage todayEuropean associationஒன்றுபட்டது மாநிலங்களில்கோட்டை துளைலி ஐயூஎட் சுஸ்மான்சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம்ஐரோப்பிய சங்கம்

PD-1 Inhibitor Shows Benefit in Nasopharyngeal Cancer

Toripalimab plus first-line chemo improved survival in recurrent/metastatic disease

United statesMike bassettRui hua xuJulier gralowAmerican society of clinical oncologySun yat sen university cancer centerAmerican societyClinical oncologyMedical officerExecutive vice president julieNasopharyngeal carcinomaPd 1 inhibitorஒன்றுபட்டது மாநிலங்களில்மைக் பாசெட்அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல்சூரியன் யத் சென் பல்கலைக்கழகம் புற்றுநோய் மையம்

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | Comunicados | Edición USA

Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | Comunicados | Edición USA
efe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from efe.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoPatricia keeganDenny lanfearJunshi bioscienceEli lillyRuihua xuMcdavid stilwellJunshi biosciencesCoherus biosciencesZhi liSheryl seapyAmerican society of clinical oncologyExchange commission onCoherus biosciences incShanghai junshi biosciences co ltd

New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer

New Drug Toripalimab Improves Survival in Nasopharyngeal Cancer
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

United statesJared weissJunshi bioscienceJulie gralowRui hua xuUniversity of washingtonAmerican society of clinical oncologyDrug administrationUniversity of north carolinaSun yat sen university cancer centerAmerican societyClinical oncologyNorth carolinaMedscape medicalShanghai junshiஒன்றுபட்டது மாநிலங்களில்

HKUMed researchers unveil a novel molecular mechanism underlying liver cancer drug resistance and tumour recurrence

Researchers at the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) have uncovered a novel signalling pathway triggered by a protein called FUT1 to promote cancer stemness, contributing to drug resistance and tumour recurrence of liver c

Hong kongGuan xinyuanRakesh sharmaYun jingpingStephanie maYu huajianLi chi hanDepartment of applied biologyCentre for panoromic sciencesHong kong polytechnic universityProfessor of the school biomedical sciencesChemical technologyDepartment of surgeryDepartment of clinical oncologySun yat sen university cancer centerUniversity of hong kong hkumed